{"success":true,"data":{"pressRelease":{"id":"159311","rtpr_id":"nGNX1RNhp6-20261002","ticker":"CELC","exchange":"NASDAQ","all_tickers":["CELC"],"title":"Celcuity Appoints David Gryska To Its Board Of Directors","author":"Globe Newswire","published_at":"2026-10-02T12:00:00.331Z","article_body":"MINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a\nbiotechnology company focused on developing and commercializing targeted\ntherapies for the treatment of multiple solid tumor indications, today\nannounced the appointment of David W. Gryska to its Board of Directors. Mr.\nGryska is a seasoned executive who brings over 35 years of strategic and\nfinancial leadership experience in the life sciences industry to Celcuity,\nincluding advising early-stage biotechnology companies.\n\n“On the heels of our first FDA approval for REVTORPYK™, we are pleased to\nwelcome David to our Board of Directors as we transition into a\ncommercial-stage company,” said Brian Sullivan, Chief Executive Officer and\nco-founder of Celcuity. “David's extensive experience as a Chief Financial\nOfficer and board member of a number of pharmaceutical companies, through\nperiods of significant clinical development and commercial growth makes him an\noutstanding addition to our Board. We are confident he will provide valuable\nexpertise as we execute the launch of REVTORPYK, advance our clinical\ndevelopment programs, and continue building the capabilities needed to support\nlong-term growth.”\n\nPrior to his retirement, Mr. Gryska served as Executive Vice President and\nChief Financial Officer of Incyte Corporation; and Senior Vice President and\nChief Financial Officer of Celgene Corporation. Mr. Gryska also served as\nSenior Vice President and Chief Financial Officer as well as Vice President of\nFinance and Chief Financial Officer at Scios, Inc. Earlier in his career, Mr.\nGryska served as a partner at Ernst & Young LLP in California.\n\nThroughout the past 25 years, Mr. Gryska has served on the Boards of eight\npublic biotechnology companies and currently serves on the Board of Directors\nof Definium Therapeutics. He previously served on the Boards of Directors of\nSeagen Inc. for more than 15 years, Forte Biosciences, Aerie Pharmaceuticals,\nand GW Pharmaceuticals. Mr. Gryska holds a B.A. in Accounting and Finance from\nLoyola University and an MBA from Golden Gate University.\n\n“Celcuity is entering an exciting new chapter, with the company poised for\nsignificant growth over the next few years following the FDA approval and\ncommercial launch of REVTORPYK in advanced breast cancer,” said Mr. Gryska.\n“I look forward to supporting Brian and Celcuity’s experienced leadership\nteam as we build on this momentum, advance gedatolisib in additional solid\ntumor indications, and work to bring meaningful benefits to more patients.”\n\nAbout Celcuity\nCelcuity is a biotechnology company focused on developing and commercializing\ntargeted therapies for the treatment of multiple solid tumor indications. The\ncompany's first FDA-approved product is REVTORPYK (gedatolisib), a potent,\npan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM\npathway. Its mechanism of action and pharmacokinetic properties are\ndifferentiated from other currently approved and investigational therapies\nthat target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial,\nVIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or\nwithout palbociclib, for the treatment of patients with HR+/HER2- ABC. Data\nfrom this trial is the basis for FDA approval of REVTORPYK for use in adult\npatients with HR+/HER2- ABC without a PIK3CA mutation detected following\nprogression on or after treatment with at least one line of endocrine therapy\nin the metastatic setting. Results for the PIK3CA mutant cohort of the\nVIKTORIA-1 study have been released. Our Phase 3 clinical trial, VIKTORIA-2,\nis an ongoing trial incorporating two independent studies, Study 1 and Study\n2, in two separate cohorts of patients with ABC who are treatment-naive in the\nadvanced setting. Study 1 is evaluating gedatolisib in combination with\npalbociclib and fulvestrant as first-line treatment for patients with\nendocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in\ncombination with palbociclib and letrozole as first-line treatment for\npatients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial,\nCELC-G-201, evaluating gedatolisib in combination with darolutamide in\npatients with metastatic castration-resistant prostate cancer, is ongoing.\nMore detailed information about Celcuity’s active clinical trials can be\nfound at ClinicalTrials.gov\n(https://www.globenewswire.com/Tracker?data=-qynwL8jASb3SisF57OA-q8jGtuwYo6CeRb4v-0XuDTxWoKapS8twQdFgxvEbzqcaXwYgYk1OUKdj4BvdAFdgMKNjEaKGJFkZLcyULbbxG3vy5kLY_P4HFg2QQ_wmPZlo0oNt6czM61ihYpSiO0OTXzrm5B__Rgw0oHXSKuknBMs61J-NTsS7m4hk58aiElD).\nCelcuity is headquartered in Minneapolis. Further information about Celcuity\ncan be found at www.celcuity.com. Follow us on LinkedIn \n(https://www.globenewswire.com/Tracker?data=eLOs1LsiNnPdHF-HL3OpoMFLycUUZtZOR1T0wqPypmp__oE8-Az1dV7TrSyH6kjjkai-7qpivEdL0hpC3Z91srHqBQLvvgNR4vhzLnREdkc=)and X\n(https://www.globenewswire.com/Tracker?data=dDH9jnb8D0NjVxujpztfZIEYzAsTsFLTTO54V4ADRegnTCKCRVZB5yoNQQ_g6t1yO6euTBxoYaRXb5tGWehUYA==).\n\nForward-Looking Statements\nThis press release contains statements that constitute \"forward-looking\nstatements\" within the meaning of the Private Securities Litigation Reform Act\nof 1995 including statements relating to REVTORPYK and the potential\ntherapeutic benefits of gedatolisib; the size, design and timing of the\nCompany’s clinical trials; the Company’s interpretation of clinical trial\ndata; the status and timing of the submission, and the FDA’s review, of the\nCompany’s supplemental New Drug Application (“sNDA”) for REVTORPYK, and\nfor making comparable filings with other regulatory authorities outside the\nU.S.; the market opportunity for REVTORPYK; the Company’s expectations\nregarding the timing of and its ability to commercialize REVTORPYK; the\nCompany’s strategy, marketing and commercialization plans, including the\nbenefits of strategic decisions regarding studies and trials; other\nexpectations with respect to gedatolisib, including subcutaneous formulations\nto support potential future indications for gedatolisib regimens; the\nCompany’s anticipated use of cash; and the strength of its balance sheet.\nWords such as, but not limited to, “look forward to,” “believe,”\n“expect,” “anticipate,” “estimate,” “intend,” \"confidence,\"\n\"encouraged,\" “potential,” “plan,” “targets,” “likely,”\n“may,” “will,” “would,” “should” and “could,” and similar\nexpressions or words identify forward-looking statements. The forward-looking\nstatements included in this press release are based on management's current\nexpectations and beliefs which are subject to a number of risks, uncertainties\nand factors, including that the Company’s topline clinical results are based\non an ongoing analysis of efficacy and safety data and such data may change\nfollowing a more comprehensive review of the data related to the clinical\ntrial; unforeseen delays in the Company’s clinical trials or the submission,\nand FDA’s review of, its sNDA for REVTORPYK; the Company’s ability to\nobtain regulatory approval of its sNDA and maintain regulatory approvals to\ncommercialize REVTORPYK in the U.S. and obtain regulatory approval of\ngedatolisib outside the U.S., and the market acceptance of REVTORPYK; the\ndevelopment of therapies and tools competitive with gedatolisib; and the\nCompany’s ability to access capital upon favorable terms. In addition, all\nforward-looking statements are subject to other risks detailed in the\nCompany’s Annual Report on Form 10-K for the year ended December 31, 2025,\nas such risks may be updated in its subsequent filings with the Securities and\nExchange Commission. You are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof. All\nforward-looking statements are qualified in their entirety by these cautionary\nstatements, and the Company undertakes no obligation to revise or update this\npress release to reflect events or circumstances after the date hereof.\n\nContacts: \n\nCelcuity Inc. \nBrian Sullivan, bsullivan@celcuity.com \nVicky Hahne, vhahne@celcuity.com \n(763) 392-0123  \nJodi Sievers, jsievers@celcuity.com\n(415) 494-9924\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/dab74495-313f-47dd-a6cb-b42a7f024edd)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1RNhp6-20261002","title":"Celcuity Appoints David Gryska To Its Board Of Directors","author":"Globe Newswire","ticker":"CELC","created":"2026-10-02T12:00:00.331Z","tickers":["CELC"],"exchange":"NASDAQ","article_body":"MINNEAPOLIS, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a\nbiotechnology company focused on developing and commercializing targeted\ntherapies for the treatment of multiple solid tumor indications, today\nannounced the appointment of David W. Gryska to its Board of Directors. Mr.\nGryska is a seasoned executive who brings over 35 years of strategic and\nfinancial leadership experience in the life sciences industry to Celcuity,\nincluding advising early-stage biotechnology companies.\n\n“On the heels of our first FDA approval for REVTORPYK™, we are pleased to\nwelcome David to our Board of Directors as we transition into a\ncommercial-stage company,” said Brian Sullivan, Chief Executive Officer and\nco-founder of Celcuity. “David's extensive experience as a Chief Financial\nOfficer and board member of a number of pharmaceutical companies, through\nperiods of significant clinical development and commercial growth makes him an\noutstanding addition to our Board. We are confident he will provide valuable\nexpertise as we execute the launch of REVTORPYK, advance our clinical\ndevelopment programs, and continue building the capabilities needed to support\nlong-term growth.”\n\nPrior to his retirement, Mr. Gryska served as Executive Vice President and\nChief Financial Officer of Incyte Corporation; and Senior Vice President and\nChief Financial Officer of Celgene Corporation. Mr. Gryska also served as\nSenior Vice President and Chief Financial Officer as well as Vice President of\nFinance and Chief Financial Officer at Scios, Inc. Earlier in his career, Mr.\nGryska served as a partner at Ernst & Young LLP in California.\n\nThroughout the past 25 years, Mr. Gryska has served on the Boards of eight\npublic biotechnology companies and currently serves on the Board of Directors\nof Definium Therapeutics. He previously served on the Boards of Directors of\nSeagen Inc. for more than 15 years, Forte Biosciences, Aerie Pharmaceuticals,\nand GW Pharmaceuticals. Mr. Gryska holds a B.A. in Accounting and Finance from\nLoyola University and an MBA from Golden Gate University.\n\n“Celcuity is entering an exciting new chapter, with the company poised for\nsignificant growth over the next few years following the FDA approval and\ncommercial launch of REVTORPYK in advanced breast cancer,” said Mr. Gryska.\n“I look forward to supporting Brian and Celcuity’s experienced leadership\nteam as we build on this momentum, advance gedatolisib in additional solid\ntumor indications, and work to bring meaningful benefits to more patients.”\n\nAbout Celcuity\nCelcuity is a biotechnology company focused on developing and commercializing\ntargeted therapies for the treatment of multiple solid tumor indications. The\ncompany's first FDA-approved product is REVTORPYK (gedatolisib), a potent,\npan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM\npathway. Its mechanism of action and pharmacokinetic properties are\ndifferentiated from other currently approved and investigational therapies\nthat target PI3Kα, AKT or mTORC1 alone or together. A Phase 3 clinical trial,\nVIKTORIA-1, evaluated gedatolisib in combination with fulvestrant, with or\nwithout palbociclib, for the treatment of patients with HR+/HER2- ABC. Data\nfrom this trial is the basis for FDA approval of REVTORPYK for use in adult\npatients with HR+/HER2- ABC without a PIK3CA mutation detected following\nprogression on or after treatment with at least one line of endocrine therapy\nin the metastatic setting. Results for the PIK3CA mutant cohort of the\nVIKTORIA-1 study have been released. Our Phase 3 clinical trial, VIKTORIA-2,\nis an ongoing trial incorporating two independent studies, Study 1 and Study\n2, in two separate cohorts of patients with ABC who are treatment-naive in the\nadvanced setting. Study 1 is evaluating gedatolisib in combination with\npalbociclib and fulvestrant as first-line treatment for patients with\nendocrine-resistant HR+/HER2- ABC. Study 2 is evaluating gedatolisib in\ncombination with palbociclib and letrozole as first-line treatment for\npatients with endocrine-sensitive HR+/HER2- ABC. A Phase 1b/2 clinical trial,\nCELC-G-201, evaluating gedatolisib in combination with darolutamide in\npatients with metastatic castration-resistant prostate cancer, is ongoing.\nMore detailed information about Celcuity’s active clinical trials can be\nfound at ClinicalTrials.gov\n(https://www.globenewswire.com/Tracker?data=-qynwL8jASb3SisF57OA-q8jGtuwYo6CeRb4v-0XuDTxWoKapS8twQdFgxvEbzqcaXwYgYk1OUKdj4BvdAFdgMKNjEaKGJFkZLcyULbbxG3vy5kLY_P4HFg2QQ_wmPZlo0oNt6czM61ihYpSiO0OTXzrm5B__Rgw0oHXSKuknBMs61J-NTsS7m4hk58aiElD).\nCelcuity is headquartered in Minneapolis. Further information about Celcuity\ncan be found at www.celcuity.com. Follow us on LinkedIn \n(https://www.globenewswire.com/Tracker?data=eLOs1LsiNnPdHF-HL3OpoMFLycUUZtZOR1T0wqPypmp__oE8-Az1dV7TrSyH6kjjkai-7qpivEdL0hpC3Z91srHqBQLvvgNR4vhzLnREdkc=)and X\n(https://www.globenewswire.com/Tracker?data=dDH9jnb8D0NjVxujpztfZIEYzAsTsFLTTO54V4ADRegnTCKCRVZB5yoNQQ_g6t1yO6euTBxoYaRXb5tGWehUYA==).\n\nForward-Looking Statements\nThis press release contains statements that constitute \"forward-looking\nstatements\" within the meaning of the Private Securities Litigation Reform Act\nof 1995 including statements relating to REVTORPYK and the potential\ntherapeutic benefits of gedatolisib; the size, design and timing of the\nCompany’s clinical trials; the Company’s interpretation of clinical trial\ndata; the status and timing of the submission, and the FDA’s review, of the\nCompany’s supplemental New Drug Application (“sNDA”) for REVTORPYK, and\nfor making comparable filings with other regulatory authorities outside the\nU.S.; the market opportunity for REVTORPYK; the Company’s expectations\nregarding the timing of and its ability to commercialize REVTORPYK; the\nCompany’s strategy, marketing and commercialization plans, including the\nbenefits of strategic decisions regarding studies and trials; other\nexpectations with respect to gedatolisib, including subcutaneous formulations\nto support potential future indications for gedatolisib regimens; the\nCompany’s anticipated use of cash; and the strength of its balance sheet.\nWords such as, but not limited to, “look forward to,” “believe,”\n“expect,” “anticipate,” “estimate,” “intend,” \"confidence,\"\n\"encouraged,\" “potential,” “plan,” “targets,” “likely,”\n“may,” “will,” “would,” “should” and “could,” and similar\nexpressions or words identify forward-looking statements. The forward-looking\nstatements included in this press release are based on management's current\nexpectations and beliefs which are subject to a number of risks, uncertainties\nand factors, including that the Company’s topline clinical results are based\non an ongoing analysis of efficacy and safety data and such data may change\nfollowing a more comprehensive review of the data related to the clinical\ntrial; unforeseen delays in the Company’s clinical trials or the submission,\nand FDA’s review of, its sNDA for REVTORPYK; the Company’s ability to\nobtain regulatory approval of its sNDA and maintain regulatory approvals to\ncommercialize REVTORPYK in the U.S. and obtain regulatory approval of\ngedatolisib outside the U.S., and the market acceptance of REVTORPYK; the\ndevelopment of therapies and tools competitive with gedatolisib; and the\nCompany’s ability to access capital upon favorable terms. In addition, all\nforward-looking statements are subject to other risks detailed in the\nCompany’s Annual Report on Form 10-K for the year ended December 31, 2025,\nas such risks may be updated in its subsequent filings with the Securities and\nExchange Commission. You are cautioned not to place undue reliance on these\nforward-looking statements, which speak only as of the date hereof. All\nforward-looking statements are qualified in their entirety by these cautionary\nstatements, and the Company undertakes no obligation to revise or update this\npress release to reflect events or circumstances after the date hereof.\n\nContacts: \n\nCelcuity Inc. \nBrian Sullivan, bsullivan@celcuity.com \nVicky Hahne, vhahne@celcuity.com \n(763) 392-0123  \nJodi Sievers, jsievers@celcuity.com\n(415) 494-9924\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/dab74495-313f-47dd-a6cb-b42a7f024edd)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-02T12:00:00.804752034Z","server_sent_at_ms":1790942400804},"received_at":"2026-10-02T12:00:00.855Z","source_url":null},"analysis":{"id":"147921","press_release_id":"159311","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"board_change","narrative":"Celcuity appointed David W. Gryska to its Board of Directors, adding a life-sciences executive with over 35 years of strategic and financial leadership experience.\n\nGryska previously served as CFO of Incyte, Celgene, and Scios, and has held board seats at eight public biotech companies over 25 years, including more than 15 years at Seagen.\n\nThe appointment follows Celcuity's first FDA approval of REVTORPYK (gedatolisib) in advanced breast cancer, and CEO Brian Sullivan framed Gryska's hire as supporting the company's transition into a commercial-stage business.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Commercial-readiness signal: Celcuity adds a big-pharma CFO veteran to its board post-REVTORPYK approval."},"keyFigures":{},"quotedText":"On the heels of our first FDA approval for REVTORPYK™, we are pleased to welcome David to our Board of Directors as we transition into a commercial-stage company","namedEntities":{"people":[{"name":"David W. Gryska","role":"New board member; former EVP & CFO of Incyte and former SVP & CFO of Celgene and Scios"},{"name":"Brian Sullivan","role":"CEO and co-founder of Celcuity"}],"products":["REVTORPYK (gedatolisib)"],"companies":[{"name":"Celcuity Inc.","ticker":"CELC","relationship":"filer"},{"name":"Incyte Corporation","relationship":"Gryska's former employer"},{"name":"Celgene Corporation","relationship":"Gryska's former employer"},{"name":"Scios, Inc.","relationship":"Gryska's former employer"},{"name":"Seagen Inc.","relationship":"Gryska's former board seat"},{"name":"Definium Therapeutics","relationship":"Gryska's current board seat"},{"name":"Forte Biosciences","relationship":"Gryska's former board seat"},{"name":"Aerie Pharmaceuticals","relationship":"Gryska's former board seat"},{"name":"GW Pharmaceuticals","relationship":"Gryska's former board seat"},{"name":"Ernst & Young LLP","relationship":"Gryska's former employer (partner)"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Routine board appointment, but the addition of a former CFO of Incyte and Celgene with deep commercial-stage biotech board experience is a quality hire as Celcuity transitions to commercial operations post-REVTORPYK approval. Not an executive departure or other market-moving binary event."},"tickerRelevance":{"others":[],"primary":"CELC"},"globalImportance":18,"audienceRelevance":25,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap biotech","eventGravity":"routine board appointment","qualitySignal":"former Incyte/Celgene CFO adds commercialization credibility","issuerAuthored":true}},"event_type":"board_change","event_type_secondary":null,"sentiment":"bullish","material_impact_score":2,"narrative":"Celcuity appointed David W. Gryska to its Board of Directors, adding a life-sciences executive with over 35 years of strategic and financial leadership experience.\n\nGryska previously served as CFO of Incyte, Celgene, and Scios, and has held board seats at eight public biotech companies over 25 years, including more than 15 years at Seagen.\n\nThe appointment follows Celcuity's first FDA approval of REVTORPYK (gedatolisib) in advanced breast cancer, and CEO Brian Sullivan framed Gryska's hire as supporting the company's transition into a commercial-stage business.","key_figures":{},"named_entities":{"people":[{"name":"David W. Gryska","role":"New board member; former EVP & CFO of Incyte and former SVP & CFO of Celgene and Scios"},{"name":"Brian Sullivan","role":"CEO and co-founder of Celcuity"}],"products":["REVTORPYK (gedatolisib)"],"companies":[{"name":"Celcuity Inc.","ticker":"CELC","relationship":"filer"},{"name":"Incyte Corporation","relationship":"Gryska's former employer"},{"name":"Celgene Corporation","relationship":"Gryska's former employer"},{"name":"Scios, Inc.","relationship":"Gryska's former employer"},{"name":"Seagen Inc.","relationship":"Gryska's former board seat"},{"name":"Definium Therapeutics","relationship":"Gryska's current board seat"},{"name":"Forte Biosciences","relationship":"Gryska's former board seat"},{"name":"Aerie Pharmaceuticals","relationship":"Gryska's former board seat"},{"name":"GW Pharmaceuticals","relationship":"Gryska's former board seat"},{"name":"Ernst & Young LLP","relationship":"Gryska's former employer (partner)"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T12:00:06.579Z","global_importance":18,"audience_relevance":25,"importance_components":{"tickerTier":"small-cap biotech","eventGravity":"routine board appointment","qualitySignal":"former Incyte/Celgene CFO adds commercialization credibility","issuerAuthored":true}},"durationMs":5694,"modelName":"glm-5.3-flashx"}}